Site search
2831 results for '' found
The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)
The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)
/
DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)
DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)
/
Hypothermic Oxygenated Perfusion (HOPE) in Donation after Circulatory Death (DCD) for Heart Transplantation (Registration Pending)
Hypothermic Oxygenated Perfusion (HOPE) in Donation after Circulatory Death (DCD) for Heart Transplantation (Registration Pending)
/
Targeted treatment for people with dysfunctional breathing and difficult asthma (ACTRN12624001285549)
Targeted treatment for people with dysfunctional breathing and difficult asthma (ACTRN12624001285549)
/
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)
/
Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)
Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)
/
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (NCT06137118)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (NCT06137118)
/
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04
/
An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Scl
An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Scl
/
Phase I/II, open label, multicenter study of YTB323 in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (NCT03960840)
Phase I/II, open label, multicenter study of YTB323 in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (NCT03960840)
/